Yes, all ACE inhibitors can cause a dry, persistent cough. This side effect is tied to the way the entire drug class works, not to any one specific medication. Somewhere between 4% and 35% of people taking an ACE inhibitor develop this cough, with the wide range reflecting differences across populations and how the cough is measured in studies.
Why Every ACE Inhibitor Carries This Risk
ACE inhibitors lower blood pressure by blocking an enzyme that narrows blood vessels. But that same enzyme also breaks down certain signaling molecules, particularly bradykinin and substance P, in the lungs. When the enzyme is blocked, these molecules build up in the airways. Bradykinin sensitizes nerve fibers in the throat and lungs, triggering a reflex that constricts airway smooth muscle and produces a cough.
Because every ACE inhibitor works by blocking this same enzyme, every one of them allows bradykinin to accumulate. Switching from one ACE inhibitor to another (say, from lisinopril to enalapril) occasionally helps individual patients, but it does not reliably eliminate the problem. The underlying mechanism is identical across the class.
What the Cough Feels Like
The cough is dry and nonproductive, meaning it doesn’t bring up mucus. Many people describe a persistent tickle or scratchy sensation in the back of the throat that triggers repeated bouts of coughing. It tends to be worse at night and can be disruptive enough to interfere with sleep, conversation, or daily life.
One tricky aspect is timing. The cough can appear within hours of the very first dose, or it can develop weeks to months after you’ve been on the medication without any issues. That delayed onset makes it easy to blame allergies, a cold, or something else entirely before connecting it to the medication.
Who Is More Likely to Develop It
Not everyone on an ACE inhibitor gets the cough, but certain groups face higher odds. Women are more commonly affected than men. People of East Asian descent and those with a history of smoking have roughly two and a half times the risk compared to the general population on these drugs. If you fall into more than one of these categories, the likelihood increases further.
How It Compares to Other Blood Pressure Medications
A large network meta-analysis comparing ACE inhibitors against other drug classes put the cough risk into sharp perspective. People on ACE inhibitors were 3.2 times more likely to develop a cough than those on ARBs (a related class of blood pressure medication) and 6.5 times more likely than those on calcium channel blockers.
Ramipril, one of the most widely prescribed ACE inhibitors, showed particularly high cough rates. In the ONTARGET trial, which enrolled over 25,000 participants, 4.2% of people on ramipril discontinued treatment because of cough, compared to just 1.1% on an ARB called telmisartan. That difference was statistically significant and has been replicated in other analyses.
ARBs lower blood pressure through a different step in the same hormonal pathway. They do not block the enzyme responsible for breaking down bradykinin, so they sidestep the main trigger for the cough. ARBs are not completely cough-free (they still carry about twice the cough risk of calcium channel blockers), but they represent a major improvement over ACE inhibitors for people who are susceptible.
How Long It Takes to Go Away
Once you stop the medication, the cough typically resolves within one to four weeks as bradykinin levels in the lungs return to normal. In some cases, though, the cough can linger for up to three months. This gradual resolution sometimes leads people to doubt the connection, especially if they expected the cough to disappear overnight.
If a cough appeared after starting an ACE inhibitor and you’re unsure whether the drug is the cause, the clearest test is a supervised trial off the medication. A cough that clears within a few weeks of stopping and returns when the drug is restarted is strong evidence that the ACE inhibitor is responsible.
What Happens if You Need to Switch
For people who develop a bothersome cough, the most common next step is switching to an ARB. ARBs provide similar cardiovascular benefits for most conditions that ACE inhibitors treat, including high blood pressure, heart failure, and kidney protection in diabetes. Calcium channel blockers are another option, particularly for patients whose primary concern is blood pressure control.
The choice depends on your specific health situation. People at higher baseline risk for cough, such as women, East Asian patients, or smokers, may benefit from starting on an ARB or calcium channel blocker in the first place rather than trying an ACE inhibitor and waiting to see if the cough develops.